Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia

In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels and lowering glucocorticoid doses in pediatric participants with classic congenital adrenal hyperplasia.

​   The New England Journal of Medicine: Search Results in Endocrinology